Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


mo.gray@ndph.ox.ac.uk


01865 743 542

Mo Gray

Clinical Trial Manager

Mo joined Oxford Population Health in March 2012, and is currently working as a Clinical Trials Manager in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) on the EASi-KIDNEY trial. EASi-KIDNEY is an international, multi-centre, randomised double-blind placebo-controlled trial assessing whether a new drug vicadrostat (BI 690517), reduces the risk of kidney disease progression, hospitalisation for heart failure or death from cardiovascular disease in people with chronic kidney disease when it is added to standard care including empagliflozin. Mo is currently managing four overseas regions in the study.

Mo has previously worked on other CTSU trials: HPS2-THRIVE; HPS3-REVEAL; ACST-2; and EMPA-KIDNEY.

Before joining CTSU, Mo had considerable experience working in: Pharmaceutical Quality Assurance, University Research and Scientific Administrator roles.